Market in Spain is around 26 million patients while the greater London area stands at nine million
News
Enrolment concluded for Valneva’s chikungunya vaccine
Phase 3 trial of single-shot chikungunya vaccine candidate unfolds among an adolescent cohort
Positive results for Ipsen’s Cabometyx in combination with nivolumab
Benefits were identified with Cabometyx in combination with nivolumab across all efficacy measures
NHS to receive further COVID-19 vaccines from RMI
Collaboration continues to be focused on reaching locations where temporary clinics cannot be easily set up
Cardiff University and Astex in drug discovery collaboration
Partnership will focus on essential new therapies across neurodegenerative diseases
Vygon and University hospital of Wales in heart patient partnership
Collaboration has created method for heart failure patients to receive at-home treatment
Positive data from LEO Pharma’s delgocitinib cream trial
Study involves the treatment of adults with moderate-to-severe chronic hand eczema
Bio&Bio’s toxic shock syndrome vaccine research concluded
Positive results showed the TSST-1 vaccine is effective with immunisation lasting for at least two years
Alvotech proposed biosimilar to Stelara accepted by EMA
The companies anticipate that the EMA could also recommend marketing authorisation for AVT04
Pharmacists to receive further mental health training
The pathway is a programme designed to develop pharmacists’ knowledge of mental health among patients
NICE fails to recommend Boehringer Ingelheim and Lilly Alliance’s empagliflozin
The treatment has been developed to treat certain chronic heart failure patients and is approved elsewhere
Vital funding established for Evonetix projects
Financing will allow company’s development of DNA synthesis chip technology to commercial scale
EU approves AstraZeneca Forxiga for use across the EU
Milestone therapy concerns the treatment of patients with symptomatic chronic heart failure
Kidney Cancer UK makes NICE plea
Charity highlights the need to find kidney cancer early and for better guidance among doctors
Alvotech and Advanz link-up for Xolair drive
Alvotech will be responsible for supply and Advanz will oversee commercialisation of biosimilar
